Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Colca JR; VanderLugt JT; Adams WJ; Shashlo A; McDonald WG; Liang J; Zhou R; Orloff DG; Clinical Pharmacology And Therapeutics, 2013, vol. 93, issue 4, p 352, ISSN 15326535. ISBN 15326535.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef